NL300243I1 - Protein formulations. - Google Patents

Protein formulations.

Info

Publication number
NL300243I1
NL300243I1 NL300243C NL300243C NL300243I1 NL 300243 I1 NL300243 I1 NL 300243I1 NL 300243 C NL300243 C NL 300243C NL 300243 C NL300243 C NL 300243C NL 300243 I1 NL300243 I1 NL 300243I1
Authority
NL
Netherlands
Prior art keywords
protein formulations
pharmaceutical formulations
osteoporosis
useful
concentration
Prior art date
Application number
NL300243C
Other languages
Dutch (nl)
Other versions
NL300243I2 (en
Original Assignee
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp
Publication of NL300243I1 publication Critical patent/NL300243I1/en
Publication of NL300243I2 publication Critical patent/NL300243I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The present invention relates to pharmaceutical formulations comprising human parathyroid hormone at a concentration from 0.3 to 10 mg/ml, a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier. The said pharmaceutical formulations are useful for the treatment of bone related disorders such as osteoporosis.
NL300243C 1998-04-28 2006-10-17 Protein formulations. NL300243I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (en) 1998-04-28 1998-04-28 Protein formulation
PCT/CA1999/000376 WO1999055353A2 (en) 1998-04-28 1999-04-26 Protein formulations

Publications (2)

Publication Number Publication Date
NL300243I1 true NL300243I1 (en) 2006-12-01
NL300243I2 NL300243I2 (en) 2007-02-01

Family

ID=20411122

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300243C NL300243I2 (en) 1998-04-28 2006-10-17 Protein formulations.

Country Status (24)

Country Link
US (1) US20050209144A1 (en)
EP (1) EP1079803B1 (en)
JP (2) JP4733267B2 (en)
KR (1) KR100579872B1 (en)
CN (1) CN1172658C (en)
AT (1) ATE273693T1 (en)
AU (2) AU766514B2 (en)
BR (1) BR9909958A (en)
CA (1) CA2329800C (en)
CY (1) CY2006006I2 (en)
DE (3) DE122006000057I1 (en)
DK (1) DK1079803T3 (en)
ES (1) ES2224637T3 (en)
FR (1) FR06C0032I2 (en)
HK (1) HK1041218B (en)
IL (1) IL139320A (en)
LU (1) LU91281I2 (en)
NL (1) NL300243I2 (en)
NZ (1) NZ508269A (en)
PT (1) PT1079803E (en)
SE (1) SE9801495D0 (en)
SI (1) SI1079803T1 (en)
WO (1) WO1999055353A2 (en)
ZA (1) ZA200006040B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (en) * 1998-04-28 1998-04-28 Astra Ab Protein formulation
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
AU2007322334B2 (en) 2006-10-03 2011-12-22 Ipsen Pharma S.A.S. Method of drug delivery for bone anabolic protein
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
FR2925333B1 (en) * 2007-12-19 2012-04-13 Farid Bennis PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES
JP2009091363A (en) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Stabilized aqueous injectable solution of pth
JP2013512688A (en) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ Methods of using black bear parathyroid hormone and black bear parathyroid hormone
KR101891673B1 (en) * 2011-06-07 2018-08-27 아사히 가세이 파마 가부시키가이샤 Freeze-dried preparation containing high-purity pth and method for producing same
CN103301058A (en) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 Composition for teriparatide injection, and preparation method and preparation thereof
CN113750091A (en) 2015-04-29 2021-12-07 雷迪厄斯制药公司 Methods for treating cancer
CN106309358A (en) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 Human parathyroid hormone-containing pharmaceutical composition and preparing method and use thereof
KR102322802B1 (en) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic form of RAD1901-2HCL
CN108333360A (en) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 Gastrin-releasing peptide precursor dilution and its application and kit
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
JP6577683B2 (en) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 Liquid pharmaceutical composition containing teriparatide having excellent stability
CN108159404B (en) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 Recombinant human parathyroid hormone preparation and preparation method thereof
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (en) * 1989-10-27 1991-05-08 Forssmann Wolf Georg DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JP2662842B2 (en) * 1991-12-09 1997-10-15 旭化成工業株式会社 Parathyroid hormone stabilizing composition
KR0131678B1 (en) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 Stabilized parathyroid hormone composition
JP3717925B2 (en) * 1992-09-29 2005-11-16 ネクター セラピューティクス Pulmonary introduction of active fragments of parathyroid hormone
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH09157294A (en) * 1995-06-15 1997-06-17 Takeda Chem Ind Ltd Parathyroid hormone derivative
DE19538687A1 (en) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stable pharmaceutical dosage forms containing parathyroid hormone
JP4053107B2 (en) * 1996-02-01 2008-02-27 中外製薬株式会社 Preventive and therapeutic agents for thrombocytopenia
US5964807A (en) * 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
DE19733651A1 (en) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols
SE9801495D0 (en) * 1998-04-28 1998-04-28 Astra Ab Protein formulation

Also Published As

Publication number Publication date
EP1079803B1 (en) 2004-08-18
AU3591699A (en) 1999-11-16
JP2011105739A (en) 2011-06-02
SI1079803T1 (en) 2005-02-28
DE69919533D1 (en) 2004-09-23
JP2002512973A (en) 2002-05-08
PT1079803E (en) 2004-11-30
WO1999055353A2 (en) 1999-11-04
AU2004200156A1 (en) 2004-02-12
HK1041218B (en) 2005-03-18
HK1041218A1 (en) 2002-07-05
US20050209144A1 (en) 2005-09-22
FR06C0032I1 (en) 2006-11-24
KR20010052276A (en) 2001-06-25
DK1079803T3 (en) 2004-11-22
CY2006006I1 (en) 2009-11-04
JP5753692B2 (en) 2015-07-22
SE9801495D0 (en) 1998-04-28
DE69919533T2 (en) 2005-09-08
CN1172658C (en) 2004-10-27
AU2004200156B2 (en) 2005-12-15
CA2329800C (en) 2004-06-15
ES2224637T3 (en) 2005-03-01
ATE273693T1 (en) 2004-09-15
NL300243I2 (en) 2007-02-01
LU91281I2 (en) 2006-12-19
DE122006000057I1 (en) 2007-01-04
WO1999055353A3 (en) 2000-01-13
CY2006006I2 (en) 2009-11-04
IL139320A0 (en) 2001-11-25
EP1079803A2 (en) 2001-03-07
ZA200006040B (en) 2002-01-28
JP4733267B2 (en) 2011-07-27
FR06C0032I2 (en) 2007-04-27
CN1319003A (en) 2001-10-24
IL139320A (en) 2007-06-17
NZ508269A (en) 2003-12-19
KR100579872B1 (en) 2006-05-12
CA2329800A1 (en) 1999-11-04
BR9909958A (en) 2000-12-26
DE122006000057I2 (en) 2009-11-05
AU766514B2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
FR06C0032I2 (en) PROTEIN FORMULATIONS
YU83502A (en) New pharmaceutical composition
EA200501744A1 (en) PEPTIDE (VARIANTS), CONTAINING HIS COMPOSITION AND MEDICINAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ASTEROSCLEROSIS
BR0008059A (en) Compositions of valdecoxib
ES2170104T3 (en) INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS.
YU7797A (en) Combination therapy for osteosis
PT994710E (en) ADMINISTRABLE ORAL PHARMACEUTICAL COMPOSITIONS INCLUDING A BENZIDRILPIPERAZINE AND A CYCLODEXTRIN
BR9914940A (en) Method to improve the pharmacokinetics of tipranavir
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION
UY27373A1 (en) BETA-HUMAN INTERFER FORMULATIONS
PT917460E (en) CYCLOSPORINE FORMULATIONS
BR0011845A (en) Pharmaceutical complex
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
IT1307866B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INHIBITORS OF GROWTH HORMONE OR THEIR BIOLOGICALLY ACTIVE FRAGMENTS FOR TREATMENT
ATE262538T1 (en) LHRH ANALOGUES FOR THE TREATMENT OF OSTEOPOROSIS
HUP0100634A2 (en) Pharmaceutical preparations comprising pentaerytritol tetranitrate
UA30798A (en) Method of oncology patients prolonged therapy